Core Viewpoint - Kessler Topaz Meltzer & Check, LLP is investigating potential violations of federal securities laws on behalf of investors of PayPal Holdings, Inc. following a surprise leadership change announced on February 3, 2026, which indicated that the pace of change and execution was not meeting the Board's expectations [1] Company Summary - PayPal announced a leadership change, replacing its CEO, which reflects concerns regarding the company's execution and strategic direction [1] - The leadership change coincided with PayPal's fourth quarter results, suggesting potential underlying issues within the company's performance [1]

Core Viewpoint - Kyndryl Holdings, Inc. has experienced a significant decline in share price due to an internal accounting review, a delay in filing its quarterly report, and the resignation of its CFO, raising concerns about potential securities law violations [2][4]. Group 1: Company Developments - Kyndryl Holdings' shares fell more than 50% in intraday trading on February 9, 2026, following the announcement of an internal accounting review [2]. - The internal review focuses on cash management practices, related disclosures, and internal control over financial reporting, prompted by document requests from the SEC [2]. - Kyndryl does not anticipate a restatement of financials but expects to report material weaknesses in internal control over financial reporting for FY25 and the first three quarters of FY26 [2]. Group 2: Legal Investigation - Block & Leviton is investigating Kyndryl Holdings for potential securities law violations and may file an action to recover losses for affected investors [4][6]. - Investors who have lost money in Kyndryl Holdings are encouraged to contact Block & Leviton for more information on recovery options [3][5]. - The firm is recognized as a leading securities class action firm, having recovered billions for defrauded investors [7].

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for allegedly making false and misleading statements regarding its drug candidate's performance during a Phase III trial [1][2]. Group 1: Lawsuit Details - The class period for the lawsuit is from August 3, 2023, to December 26, 2025, with a deadline for lead plaintiff appointments set for April 6, 2026 [2]. - The complaint alleges that Ultragenyx created falsely optimistic beliefs about its drug candidate's performance, failing to achieve statistically significant endpoints despite positive communications [2]. Group 2: Investor Participation - Shareholders who purchased shares during the class period are encouraged to contact the law firm for potential lead plaintiff appointments, although such an appointment is not necessary to participate in any recovery [2][3]. Group 3: Law Firm Background - DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns through advocacy [4].

Core Viewpoint - A class action lawsuit has been filed against Mereo BioPharma Group plc for alleged violations of securities laws, specifically related to misleading statements about its clinical programs [1][2]. Group 1: Lawsuit Details - The class period for the lawsuit is from June 5, 2023, to December 26, 2025, with a deadline for lead plaintiff appointments set for April 6, 2026 [2]. - The complaint alleges that Mereo made false and misleading statements regarding its Phase 3 ORBIT and COSMIC programs, which did not meet their endpoints compared to placebo or bisphosphonate control groups [2]. Group 2: Investor Participation - Shareholders who purchased MREO shares during the class period are encouraged to contact the law firm for potential lead plaintiff appointments, although this is not necessary to participate in any recovery [2][3].

Core Viewpoint - Ralliant Corporation is under investigation for potential securities law violations following a significant drop in its stock price after reporting a $1.4 billion non-cash goodwill impairment related to its acquisition of EA Elektro-Automatik, which reflects revised long-term expectations for the business and a reduction in industry forecasts for future electric vehicle adoption [2][4]. Group 1: Company Performance - Ralliant's shares fell over 30% on February 5, 2026, after the company disclosed a $1.4 billion non-cash goodwill impairment in its Test & Measurement segment [2]. - The impairment is attributed to revised long-term expectations for the EA Elektro-Automatik acquisition and a decrease in industry forecasts regarding future electric vehicle adoption [2]. Group 2: Legal Investigation - Block & Leviton is investigating Ralliant Corporation for potential securities law violations and may file an action to recover losses for investors [4]. - Investors who have lost money on their Ralliant investment are encouraged to contact Block & Leviton for more information on recovery options [3][5]. Group 3: Investor Eligibility - Any individual who purchased Ralliant Corporation common stock and experienced a decline in share value may be eligible to participate in the investigation, regardless of whether they have sold their investment [3]. Group 4: Whistleblower Information - Individuals with non-public information about Ralliant Corporation are encouraged to assist in the investigation or report to the Securities Exchange Commission under the whistleblower program, which offers rewards of up to 30% of any successful recovery [6].

Group 1 - The DJS Law Group has announced a class action lawsuit against Picard Medical, Inc. for violations of the Securities Exchange Act of 1934 and related SEC rules [1] - The class period for the lawsuit is from September 2, 2025, to October 31, 2025, with a deadline for lead plaintiff appointments set for April 3, 2026 [2] - The complaint alleges that Picard Medical made false and misleading statements to the market, benefiting from a stock manipulation scheme that inflated its share price [2] Group 2 - Shareholders who purchased shares during the class period are encouraged to contact the DJS Law Group for potential participation in the lawsuit [2][3] - DJS Law Group specializes in securities class actions and corporate governance litigation, representing large hedge funds and alternative asset managers [4]

Core Viewpoint - The Gross Law Firm is notifying shareholders of Fermi Inc. regarding a class action lawsuit due to alleged misleading statements made by the company during a specific class period [1][4]. Group 1: Class Action Details - The class period for the lawsuit includes shares purchased during the initial public offering in October 2025 and securities acquired between October 1, 2025, and December 11, 2025 [3]. - Shareholders are encouraged to contact the Gross Law Firm for possible lead plaintiff appointment, although this is not required to participate in any recovery [1][5]. Group 2: Allegations Against Fermi Inc. - The complaint alleges that Fermi Inc. overstated tenant demand for its Project Matador campus and relied heavily on a single tenant's funding commitment for construction [4]. - It is claimed that there was a significant risk of the tenant terminating its funding commitment, which was not disclosed, leading to misleading positive statements about the company's business and prospects [4]. Group 3: Next Steps for Shareholders - Shareholders must register by March 6, 2026, to participate in the class action and will be enrolled in a portfolio monitoring system for updates on the case [5]. - There is no cost or obligation for shareholders to participate in the lawsuit [5].

Core Viewpoint - The Schall Law Firm is investigating Microsoft Corporation for potential violations of securities laws related to misleading statements and undisclosed information affecting investors [1][2]. Group 1: Investigation Details - The investigation centers on whether Microsoft issued false or misleading statements or failed to disclose critical information to investors [2]. - Following the Q2 2026 financial results announcement on January 28, 2026, Microsoft shares fell nearly 10% due to capacity constraints associated with AI [2]. - Microsoft CFO Amy Hood indicated that approximately 45% of the commercial RPO balance is from OpenAI, with the remaining balance growing by 28%, reflecting strong customer demand [2].

NEW YORK, Jan. 29, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Varonis Systems, Inc. (NASDAQ: VRNS). Shareholders who purchased shares of VRNS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE:https://securitiesclasslaw.com/securities/varonis-systems-inc-loss-submission-form/?id=183281&from=4  CLASS PERIOD: Februa ...

Core Viewpoint - DJS Law Group is investigating claims against Corcept Therapeutics for potential violations of securities laws following the FDA's Complete Response Letter regarding the company's New Drug Application for relacorilant, which led to a significant drop in share price [1][2]. Investigation Details - The investigation centers on whether Corcept made misleading statements or failed to disclose critical information to investors [2]. - On December 31, 2026, Corcept announced that the FDA issued a Complete Response Letter for relacorilant, despite acknowledging that the pivotal GRACE trial met its primary endpoint and that data from the GRADIENT trial provided confirmatory evidence [2]. - Following the FDA's announcement, Corcept's shares plummeted by more than 50% [2]. Legal Representation - DJS Law Group specializes in securities class actions and corporate governance litigation, aiming to enhance investor returns through effective advocacy [4].